Perimenopause, HRT, and Your Cholesterol
If your cholesterol has crept up in your forties or fifties, it’s almost certainly perimenopause.
It’s a reasonable-sounding theory. You started HRT, your labs later showed higher cholesterol, so the medication must have done it.
Many women do. You’re eating the same way, exercising the same way, your weight hasn’t changed much — and your cholesterol has still climbed. That’s not something you’re doing wrong. Perimenopause changes cholesterol on its own, before any medication enters the picture.[2][4]
Does perimenopause affect my cholesterol?
Yes. As estradiol drops during the menopausal transition, your cholesterol profile shifts in a direction that tends to be less heart-friendly — and this happens even if nothing else about your life has changed.[1][2][3]
The biggest changes happen in the window roughly 1 year before and 1 year after your final menstrual period. LDL and apolipoprotein B begin climbing up to 5 years before the final period and accelerate sharply around it.[2][3][4]
Why this happens
Estrogen quietly helps the liver manage cholesterol. When estradiol declines, three things happen at once:
The liver changes how it makes and clears cholesterol. LDL (the “bad” cholesterol) and triglycerides go up, and total cholesterol follows.[1][5]
HDL function drops, even when the number looks fine. This is the subtle one. Your HDL level on your lab might look the same or even slightly higher, but studies of HDL particles show they become less protective during the transition — which is part of why some postmenopausal women develop heart disease despite “good” HDL numbers.[2][7]
Small, dense LDL particles become more common. These are the more harmful kind of LDL — they slip into artery walls more easily than the large, fluffy kind.[8]
And this isn’t just aging. Large studies that compared menopausal status to age directly found that menopause itself accounts for a meaningful chunk of the cholesterol rise, separate from getting older.[1][4][9]
Why this gets blamed on HRT
The confusion is actually understandable. Here’s the usual sequence:
-
1
A woman enters perimenopause.Her estradiol starts to fluctuate and decline, usually in her mid-to-late forties.
-
2
Her cholesterol begins to rise.This often starts several years before her final period, but she may not know it’s happening.
-
3
She starts HRT for symptoms.Hot flashes, night sweats, sleep issues — these are why she sought help in the first place.
-
4
Her next lipid panel shows higher numbers.And the most recent change in her care is the HRT. So it’s the easy thing to blame.
- 5
Does transdermal HRT affect cholesterol?
Yes — in a good way. Transdermal estradiol (the patch, gel, or spray) generally moves cholesterol in a more favorable direction, not a worse one.[6][10][11]
Transdermal estradiol also produces larger LDL particles — the fluffier, less-harmful kind — which is another small benefit for heart health.[11]
One important distinction: pill vs. patch
This is where some of the confusion comes from. Estrogen taken as a pill goes through the liver first. Estrogen absorbed through the skin mostly skips the liver and goes straight into the bloodstream. That difference changes how it affects your cholesterol.[10][11]
Oral estrogen does raise HDL more than transdermal, but at the cost of often raising triglycerides and giving a less favorable LDL particle profile. The 2023 American Heart Association consensus statement specifically recommends transdermal estrogen for symptomatic menopausal women with any tendency toward high triglycerides.[6]
HRT is not prescribed to treat cholesterol or to prevent heart disease. The lipid improvements from transdermal estradiol are a side benefit — not the reason to start it.[6][12]
If your lipids need treatment for cardiovascular risk, that’s a separate conversation about statins, lifestyle, and other lipid-lowering options. HRT and lipid management run on parallel tracks — not one path.
What this means for you
If your cholesterol is creeping up in your forties or fifties, the first and most likely explanation is the hormonal transition itself. If you’re on transdermal HRT, it’s almost certainly not causing the rise — and may be modestly helping.
Three practical takeaways:
Get your lipids checked during perimenopause. This is the window where meaningful changes happen, and catching them early matters for long-term cardiovascular health.[1][2]
Don’t stop your HRT over lipids alone — especially if it’s transdermal. If your cholesterol numbers change, that’s a reason to look at your full picture, not to assume the hormones are the culprit.
If lipids need treatment, treat the lipids directly. Statins and other proven cholesterol therapies exist for a reason. HRT isn’t a substitute.
Perimenopause raises cholesterol. Transdermal HRT doesn’t — and in some ways actually helps.
The rise in cholesterol so many women see in midlife is the hormonal transition doing its work, not the hormone therapy doing damage. The timing overlaps, which is why the confusion is so common — but the research is clear.
If your most recent labs show changes you want to talk through, send us a message and we’ll fold it into your plan.
Message the clinicThe research behind this page
These are the studies and guidelines we drew from. Links go to the PubMed listing or journal page for each.
- Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention — A Scientific Statement From the American Heart Association. El Khoudary SR, Aggarwal B, Beckie TM, et al. Circulation. 2020. pubmed.ncbi.nlm.nih.gov/33251828
- Are Changes in Cardiovascular Disease Risk Factors in Midlife Women Due to Chronological Aging or to the Menopausal Transition? Matthews KA, Crawford SL, Chae CU, et al. Journal of the American College of Cardiology. 2009. pubmed.ncbi.nlm.nih.gov/20082925
- Trajectories of Lipids over the Menopausal Transition: The Study of Women’s Health Across the Nation. Wu W, et al. Journal of the American Heart Association. 2023. pubmed.ncbi.nlm.nih.gov/37947109
- Unraveling the Associations of Age and Menopause with Cardiovascular Risk Factors in a Large Population-Based Study. de Kat AC, Dam V, Onland-Moret NC, et al. BMC Medicine. 2017. pubmed.ncbi.nlm.nih.gov/28049531
- Dyslipidemia Across the Menopause Transition: Mechanisms, Trajectories, and Opportunities for Cardiovascular Prevention. Castaneda R, Tatit CP, Hurtado Andrade MD, Faubion SS, Shufelt CL. Maturitas. 2026.
- Rethinking Menopausal Hormone Therapy: For Whom, What, When and How Long? Cho L, Kaunitz AM, Faubion SS, et al. Circulation. 2023. pubmed.ncbi.nlm.nih.gov/36780393
- HDL Subclasses Across the Menopause Transition (SWAN-HDL). El Khoudary SR, et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021. pubmed.ncbi.nlm.nih.gov/33267661
- The Emergence of the Metabolic Syndrome with Menopause. Carr MC. The Journal of Clinical Endocrinology and Metabolism. 2003. pubmed.ncbi.nlm.nih.gov/12788835
- The Menopausal Transition Period and Cardiovascular Risk. Mehta JM, Manson JE. Nature Reviews Cardiology. 2024.
- Effects of Transdermal Versus Oral Hormone Replacement Therapy in Postmenopause: A Systematic Review. Goldštajn MŠ, Mikuš M, Ferrari FA, et al. Archives of Gynecology and Obstetrics. 2023.
- Arterial Imaging Outcomes and Cardiovascular Risk Factors in Recently Menopausal Women (KEEPS). Harman SM, Black DM, Naftolin F, et al. Annals of Internal Medicine. 2014.
- Lipid Management in Patients With Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. Newman CB, Blaha MJ, Boord JB, et al. The Journal of Clinical Endocrinology and Metabolism. 2020.

